Immunological differences between primary and metastatic breast cancer
Author:
Funder
Breast Cancer Research Foundation
Susan Komen Foundation for the Cure
Department of Defense Breast Cancer Research Program Awards
Rosztoczy Foundation
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/11/2232/27182594/mdy399.pdf
Reference31 articles.
1. Advances in cancer immunology and cancer immunotherapy;Voena;Discov Med,2016
2. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers;Bianchini;J Clin Oncol,2010
3. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures;Karn;PLoS One,2011
4. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer;Denkert;J Clin Oncol,2010
5. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers;Denkert;J Clin Oncol,2015
Cited by 233 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer;World Journal of Clinical Cases;2024-02-06
2. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer;BMC Women's Health;2024-01-13
3. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer;Frontiers in Immunology;2024-01-03
4. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer;Journal of Experimental & Clinical Cancer Research;2024-01-03
5. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?;Current Oncology Reports;2024-01-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3